Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
|Articles|August 9, 2022
Daily OTC Pearl: Senokot-S
Author(s)Saro Arakelians, PharmD
Senokot-S is indicated for constipation relief.
Advertisement
OTC/Lifestyle Pearl of the Day: Senokot-S
Indication: Senokot-S is indicated forconstipation relief.
Insight:
- Dual action formula.
- Active Ingredients: Sennosides (8.2 mg)+A34:H34, docusate sodium (50 mg). Inactive ingredients: Dicalcium phosphate, D&C yellow #10 aluminum lake, FD&C yellow #6 aluminum lake, lecithin, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, sodium benzoate, talc, titanium dioxide.
- Adults: Take 2 tablets per day. Do not exceed 4 tablets in a day.
Source:
Advertisement
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5